Literature DB >> 31502389

Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.

Zhou Yu1, Shanshan Qin1, Haidong Wang1.   

Abstract

AIM: Liquid biopsy shows great potential in the fields of early diagnosis and prognosis in cancer. Ovarian cancer (OC) is the seventh most common cancer and the eighth most common cause of death from cancer in women. The early diagnosis of OC is vital for subsequent treatment and outcome. Here we investigated two markers: cell-free DNA concentration (cfDNA conc) and cell-free DNA integrity (cfDI) between OC patients and healthy controls.
METHODS: Age-matched OC patients and healthy controls were enrolled in this study. In total, there are 20 patients and 20 healthy controls. cfDNA conc and cfDI were calculated by arthrobacter luteus (ALU) gene using quantitative real-time polymerase chain reaction (PCR).
RESULTS: An increased cfDNA conc in OC patients compared to healthy controls was observed (mean cfDNA conc for OC patients: 1.98 ng/μL, for healthy control: 0.51 ng/μL, P = 0.02). For cfDI, the median value of OC patients is 0.49 while the median value of healthy control is 0.61 (P = 0.038). The diagnostic value of area under the curve was 0.86 for cfDNA conc and 0.72 for cfDI. When cfDNA conc and cfDI were combined, the diagnostic value was 0.90 which indicates a good diagnostic marker.
CONCLUSION: As few reports of cfDNA conc and cfDI differences between OC patients and healthy controls reported, our study shows increased cfDNA concentrations and decreased cfDI in OC patients compared to healthy controls. We also propose that cfDNA biomarkers can be potential diagnostic markers in ovarian cancer.
© 2019 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  cell-free DNA concentration; cell-free DNA integrity; diagnostic marker; ovarian cancer

Mesh:

Substances:

Year:  2019        PMID: 31502389     DOI: 10.1111/jog.14102

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  6 in total

1.  Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias.

Authors:  Esther Mettler; Christian Fottner; Neda Bakhshandeh; Anja Trenkler; Robert Kuchen; Matthias M Weber
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

2.  Plasma cfDNA as a Potential Biomarker to Evaluate the Efficacy of Chemotherapy in Gastric Cancer.

Authors:  Yuejiao Zhong; Qingyu Fan; Zhaofei Zhou; Yajing Wang; Kang He; Jianwei Lu
Journal:  Cancer Manag Res       Date:  2020-05-05       Impact factor: 3.989

Review 3.  Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?

Authors:  Ming Yu; Yu Zhu; Lichen Teng; Jialin Cui; Yajuan Su
Journal:  J Oncol       Date:  2021-04-12       Impact factor: 4.375

Review 4.  Role of liquid biopsy for thoracic cancers immunotherapy.

Authors:  Raimondo Di Liello; Flora Cimmino; Soraya Simón; Emilio Francesco Giunta; Vincenzo De Falco; Paloma Martín-Martorell
Journal:  Explor Target Antitumor Ther       Date:  2020-06-29

Review 5.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

6.  TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer.

Authors:  Silvia R Vitale; Floris H Groenendijk; Ronald van Marion; Corine M Beaufort; Jean C Helmijr; Hendrikus Jan Dubbink; Winand N M Dinjens; Patricia C Ewing-Graham; Ramon Smolders; Helena C van Doorn; Ingrid A Boere; Els M J J Berns; Jozien Helleman; Maurice P H M Jansen
Journal:  Biomolecules       Date:  2020-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.